- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04831281
ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies (SHAPE Trial)
April 11, 2024 updated by: Athira Pharma
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
This study is designed to evaluate the safety and treatment effects of fosgonimeton (ATH-1017) in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized treatment duration of 26 weeks.
Study Overview
Status
Completed
Intervention / Treatment
Detailed Description
The study is designed to evaluate the safety and treatment effects of ATH-1017 in subjects with Parkinson's Disease Dementia or Dementia with Lewy Bodies, with a randomized, double-blind, placebo-controlled, parallel-arm treatment duration of 26 weeks.
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Florida
-
Boca Raton, Florida, United States, 33486
- Parkinson's Disease and Movement Disorders Center of Boca Raton
-
West Palm Beach, Florida, United States, 33407
- Premiere Research Institute
-
-
Georgia
-
Decatur, Georgia, United States, 30030
- iResearch Atlanta, LLC
-
-
Michigan
-
Farmington Hills, Michigan, United States, 48334
- Quest Research Institute
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Summit Research Network
-
Portland, Oregon, United States, 97225
- Center for Cognitive Health
-
-
Pennsylvania
-
Plymouth Meeting, Pennsylvania, United States, 19462
- Keystone Clinical Studies LLC
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Northwest Clinical Research Center
-
Kirkland, Washington, United States, 98034
- Evergreen Health Research
-
Spokane, Washington, United States, 99202
- Inland Northwest Research LLC
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
38 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Subjects with confirmed diagnosis of Parkinson's disease or Dementia with Lewy Bodies
- MoCA score 11 to 23, inclusive, at screening
- Probable Parkinson's Disease Dementia or Lewy Body Dementia
- BMI between ≥ 16and ≤ 35 kg/m2 for females and between≥ 18 and ≤ 35 kg/m2 for males at Screening
- Reliable and capable support person/caregiver, who is willing to accept responsibility for supervising the treatment or, if required, administering study drug, and assessing the condition of the subject throughout the study in accordance with all protocol requirements
Exclusion Criteria:
- Hoehn-Yahr stage 5
- History of significant neurological disease other than PDD or DLB that may affect cognition at onset of dementia
- Subjects on deep brain stimulation
- History of brain MRI scan indicative of any other significant abnormality
- History of unexplained loss of consciousness, and epileptic fits
- Hearing test result considered unacceptable for auditory ERP P300 assessment
- Diagnosis of severe major depressive disorder even without psychotic features (GDS score [15-item scale] >7 at Screening)
- Significant suicide risk based on C-SSRS
- Significant psychosis (according to Diagnostic and Statistical Manual of Mental Disorders)
- Moderate or severe substance abuse disorder (according to DSM-5)
- Myocardial infarction or unstable angina within the last 6 months
- Clinically significant cardiac arrhythmia (including atrial fibrillation), cardiomyopathy, or cardiac conduction defect (note: pacemaker is acceptable)
- Clinically significant ECG abnormality at Screening
- Chronic kidney disease (eGFR < 45 mL/min using Cockcroft-Gault formula)
- Hepatic impairment with alanine aminotransferase or aspartate aminotransferase > 2 times the upper limit of normal, or Child-Pugh class B and C
- Malignant tumor within 3 years before Screening
- Memantine at any dose or combination
- Donepezil at 23 mg
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 40mg Dose
Daily subcutaneous injection of 40mg ATH-1017
|
Daily subcutaneous injection of ATH-1017 in a pre-filled syringe
|
Experimental: 70mg Dose
Daily subcutaneous injection of 70mg ATH-1017
|
Daily subcutaneous injection of ATH-1017 in a pre-filled syringe
|
Placebo Comparator: Placebo
Daily subcutaneous injection of Placebo
|
Daily subcutaneous injection of Placebo in a pre-filled syringe
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall treatment effect of ATH-1017 as reflected by the Global Statistical Test
Time Frame: Week 26
|
As reflected by the composite Global Statistical Test (GST)
|
Week 26
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Event-Related Potential
Time Frame: Week 2, 12, 26
|
Event-related potential (ERP) P300 latency change from baseline
|
Week 2, 12, 26
|
Cognition
Time Frame: Week 2, 12, 20, and 26
|
Alzheimer's Disease Assessment Scale-Cognitive Subscale [ADAS-Cog13] change from baseline (Range of 0 to 85, where 0 is least impairment and 85 is most severe impairment)
|
Week 2, 12, 20, and 26
|
Clinical Global Impression of Change
Time Frame: Week 12 and 26
|
Clinical Global Impression of Change (CGI-C) change from baseline (Range of 1 to 7, where 1 is marked improvement and 7 is marked worsening)
|
Week 12 and 26
|
Activities of Daily Living
Time Frame: Week 12 and 26
|
Alzheimer's Disease Cooperative Study - Activities of Daily Living, 23-item version [ADCS-ADL23] change from baseline (Range of 0 to 78, where a higher score indicates greater function)
|
Week 12 and 26
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Motor Function
Time Frame: Week 12, 26
|
Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score
|
Week 12, 26
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 20, 2022
Primary Completion (Actual)
April 19, 2023
Study Completion (Actual)
April 19, 2023
Study Registration Dates
First Submitted
April 1, 2021
First Submitted That Met QC Criteria
April 1, 2021
First Posted (Actual)
April 5, 2021
Study Record Updates
Last Update Posted (Estimated)
April 15, 2024
Last Update Submitted That Met QC Criteria
April 11, 2024
Last Verified
April 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ATH-1017-PD-0201
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia With Lewy Bodies
-
EIP Pharma IncWorldwide Clinical TrialsCompletedDementia With Lewy Bodies (DLB)United States, Netherlands
-
Osaka UniversityCompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Inc.CompletedDementias With Lewy BodiesUnited States
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
University Hospital, Strasbourg, FranceRecruitingDementia With Lewy Bodies Diagnosis | Significant Cognitive Fluctuations in DLBFrance
-
Eisai Co., Ltd.Completed
-
CND Life SciencesNational Institute on Aging (NIA)RecruitingMCI-AD, Early Stage Alzheimer's Disease | MCI-DLB, Early Stage Dementia With Lewy BodiesUnited States
-
Cognition TherapeuticsNational Institute on Aging (NIA)RecruitingDementia With Lewy BodiesUnited States
Clinical Trials on ATH-1017
-
Athira PharmaEnrolling by invitationAlzheimer DiseaseUnited States, Australia
-
Athira PharmaActive, not recruitingAlzheimer Disease | Dementia of Alzheimer TypeUnited States
-
Athira PharmaNational Institute on Aging (NIA)CompletedAlzheimer Disease | Dementia of Alzheimer TypeUnited States, Australia
-
Athira PharmaAlturas Analytics, Inc.; Labcorp Drug Development IncCompletedHealthy VolunteersUnited States
-
HanAll BioPharma Co., Ltd.NurrOn Pharmaceuticals, Inc.RecruitingHealthy VolunteersCanada
-
Athira PharmaBiotrial Inc.; Alturas Analytics, Inc.Completed
-
Athos Therapeutics IncSyneos Health; Athos Therapeutics Australia Pty LtdRecruitingAutoimmune Diseases | Inflammatory Bowel Diseases | Crohn Disease | Ulcerative ColitisAustralia
-
Relmada Therapeutics, Inc.CompletedMajor Depressive DisorderUnited States
-
Alligator Bioscience ABCompletedNeoplasms | Solid TumorSweden
-
Relmada Therapeutics, Inc.CompletedMajor Depressive DisorderUnited States